Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Subjects

Subjects :

Oncology
medicine.medical_specialty
business.industry
Bortezomib
Hematology
ta3111
ta3122
medicine.disease
Minimal residual disease
03 medical and health sciences
0302 clinical medicine
Text mining
Autologous stem-cell transplantation
030220 oncology & carcinogenesis
Internal medicine
Molecular genetics
Medicine
Remission rate
business
Dexamethasone
Multiple myeloma
030215 immunology
medicine.drug

Details

ISSN :

00071048

Volume :

160

Database :

OpenAIRE

Journal :

British Journal of Haematology

Accession number :

edsair.doi.dedup.....fd6f89d4955e04eb557cf8bed0c612f2

Full Text :

https://doi.org/10.1111/bjh.12139